Pilot Study on the Effects of Neuromuscular Taping in Parkinson's Disease Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson Disease
- Sponsor
- IRCCS San Raffaele Roma
- Enrollment
- 46
- Primary Endpoint
- Change in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating scale total score between baseline evaluations and end of treatment
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Parkinson's disease (PD) is a degenerative disorder characterized by a symptom triad consisting on: tremor, rigidity and bradykinesia . To these symptoms it is often added postural alteration that can stand in two different attitudes, such as the camptocormia and the syndrome of Pisa . Progressing in its evolution, PD becomes increasingly disabling, making it difficult or even impossible daily activities such as washing or dressing.The abnormal posture, with alteration of the limbs, the neck and trunk, is a recurring feature in PD, with a frequency of about 30%. Between 2% and 12.3% are more severe abnormalities such as camptocormia, the syndrome of Pisa and the anterocollis. Several studies disease plug in Neuromuscular Taping technique (NMT) among rehabilitative tools in degenerative neurological syndromes.
To the best of our knowledge, no applications were found in PD. Therefore, the current study was designed to evaluate quantitatively the effects of the NMT intervention on the trunk kinematics during standing position. More specifically, this study aims to compare the trunk kinematic variables of patients with PD who were treated with effective NMT versus those of the subjects who received only the pharmacological treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change in the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) rating scale total score between baseline evaluations and end of treatment
Time Frame: baseline and end of treatment (1 month)
Clinical measures were summarized as means and standard deviations for all the 46 patients.
Secondary Outcomes
- Change in the EuroQol 5 total score between baseline evaluations and end of treatment(baseline and end of treatment (1 month))
- Change in the Non Motor Symptoms scale total score between baseline evaluations and end of treatment(baseline and end of treatment (1 month))
- Change in the Freezing of Gait total score between baseline evaluations and end of treatment(baseline and end of treatment (1 month))
- Change in the Parkinson Disease Quality of life 8 total score between baseline evaluations and end of treatment(baseline and end of treatment (1 month))